Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study
In the AD+HS subgroup, improvements were observed for both AD and HS-specific outcomes. Our data, although preliminary, show that upadacitinib could be a valid therapeutic choice in the treatment of patients with AD and concomitant HS.
Authors
- Luca Calabrese (ORCID: https://orcid.org/0000-0001-6476-3689)
- Marialuisa Corbeddu (ORCID: https://orcid.org/0000-0002-4158-5717)
- Natale Schettini (ORCID: https://orcid.org/0000-0002-6693-766X)
- Tommaso Bianchelli
- E. Del Duca
- F. Russo
- F. Manzo Margiotta
- E. Antonelli
- M. Galluzzo
- G. L. Scaglione
- N. Gori
- F. Giuliani
Institutions
- University of Siena (IT)
- Università Cattolica del Sacro Cuore (IT)
- University of Pisa (IT)
- University of Rome Tor Vergata (IT)
- Scuola Superiore Sant'Anna (IT)
- University of Cagliari (IT)
- University of Ferrara (IT)
- University of Perugia (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituto Dermopatico dell'Immacolata (IT)
- Policlinico Tor Vergata (IT)
- Ospedale SS. Annunziata (IT)
- Istituto Nazionale di Riposo e Cura per Anziani (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3389/fimmu.2026.1770969
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute